Fields E D
Drug Intell Clin Pharm. 1982 Jul-Aug;16(7-8):547-52. doi: 10.1177/106002808201600703.
Nomifensine is an isoquinoline antidepressant that inhibits the reuptake of dopamine at central synapses. It also inhibits norepinephrine reuptake but is only a weak inhibitor of 5-hydroxytryptamine. Open and controlled trials comparing nomifensine with placebo and other standard antidepressants have shown it to be an effective antidepressant in divided doses up to 200 mg/d. The full dosage range of 50-200 mg/d is well tolerated, and doses can be selected to suit patient disease, age, and therapeutic response. Minimal anticholinergic and sedative side effects and no impairment of psychomotor performance make nomifensine a suitable drug for use in a wide variety of ambulatory outpatients, including the elderly. A relative lack of cardiotoxicity and epileptogenic activity add to this profile; the safety of the drug, when taken in overdose, has been documented. However, the place of nomifensine in the treatment of depression, relative to other antidepressants, is still unclear.
诺米芬辛是一种异喹啉类抗抑郁药，可抑制中枢突触处多巴胺的再摄取。它也抑制去甲肾上腺素的再摄取，但仅是5-羟色胺的弱抑制剂。将诺米芬辛与安慰剂及其他标准抗抑郁药进行比较的开放试验和对照试验表明，其在高达200mg/d的分次剂量下是一种有效的抗抑郁药。50-200mg/d的全剂量范围耐受性良好，可根据患者病情、年龄和治疗反应选择剂量。最小的抗胆碱能和镇静副作用以及对精神运动功能无损害，使诺米芬辛成为适用于包括老年人在内的各种门诊患者的药物。相对缺乏心脏毒性和致癫痫活性也增加了这一特点；该药物过量服用时的安全性已有文献记载。然而，相对于其他抗抑郁药，诺米芬辛在抑郁症治疗中的地位仍不明确。
